For the most recent call for proposals, Pfizer was interested in research projects that fell within the following therapeutic areas:
- Oncology: Targets/pathways that promote anti-tumor immune responses alone or in combination with checkpoint inhibitors; provide innate anti-tumor immune system activation; reduce or overcome tumor-induced immune suppression; or alter tumor microenvironment metabolism. Targets that promote directed tumor cell killing. Targets that address stromal heterogeneity, senescence, tumor plasticity, translational stress or protein stability. Novel cell-surface targets that enable mAb therapy.
- Inflammation and Immunology: Targets/pathways that provide immune regulation but do not involve broad-based immunosuppression including adaptive and innate immunity, Th17 lymphocyte biology, regulatory cells and tolerance induction, or immune metablolism with a focus on rheumatoid arthritis, systemic lupus, erythematosus, inflammatory bowel disease, non-alcoholic steatohepatitis, atopic dermatitis, alopecia and vitiligo. Host-microbial interactions and microbiome are of interest with focus on epithelial barrier.
- Cardiovascular and Metabolic Diseases: Targets/pathways that decrease hepatic lipid content, inflammation and the development of liver fibrosis in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Novel approaches that reduce hyperinsulinemia and hyperglycemia.
- Neuroscience: Primary focus on Alzheimer's disease and Parkinson's disease. Targets/pathways with disease modifying and symptomatic potential. Chronic neuroinflammation mechanisms impacting the pathologies of Alzheimer's disease and Parkinson’s disease.
- Rare Diseases: Targets/pathways representing novel therapeutic interventions for Hematologic (non-malignant) indications, including Haemophilia, sickle cell disease and beta-thalassemia; for skeletal and cardiac muscle diseases, including Duchenne/Becker muscular dystrophies; or for repeat expansion diseases, including Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal degeneration and myotonic dystrophy.